Moreover, an integrated analysis of safety data of RET-Is among patients with RET fusion + NSCLC with those with medullary thyroid carcinoma and other tumors should be mandatory to define if some toxicities are only drug-dependent or can be linked also to a specific disease [136,137]. Here, RET is linked to medullary thyroid gland carcinoma.